NASDAQ:STRO Sutro Biopharma - STRO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.11 -0.24 (-3.27%) (As of 02/3/2023 05:19 PM ET) Add Compare Share Share Today's Range$7.07▼$7.3950-Day Range$6.68▼$8.4552-Week Range$3.33▼$10.15Volume370,428 shsAverage Volume615,310 shsMarket Capitalization$408.61 millionP/E RatioN/ADividend YieldN/APrice Target$19.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Sutro Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside176.6% Upside$19.67 Price TargetShort InterestHealthy3.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.54) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector245th out of 1,029 stocksBiological Products, Except Diagnostic Industry38th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.67, Sutro Biopharma has a forecasted upside of 176.6% from its current price of $7.11.Amount of Analyst CoverageSutro Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.67% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 8.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 3.2 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.Search Interest14 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows2 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions87.64% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.54) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sutro Biopharma (NASDAQ:STRO) StockSutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.Read More Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Stock News HeadlinesJanuary 27, 2023 | finance.yahoo.comAre Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?January 21, 2023 | msn.comMan hit by train on tracks at SutroFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 18, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Zynex (ZYXI), Sutro Biopharma (STRO) and Amryt Pharma (AMYT)January 10, 2023 | finance.yahoo.comSutro Biopharma Posts Updated Data From Ovarian Cancer CandidateJanuary 9, 2023 | tmcnet.comSutro Biopharma Announces Update from STRO-002, LuveltamabJanuary 9, 2023 | finance.yahoo.comSutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian CancerJanuary 6, 2023 | finance.yahoo.comWith 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional ownersFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 4, 2023 | finance.yahoo.comSutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 21, 2022 | finance.yahoo.comSutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian CancerDecember 20, 2022 | msn.comVaxcyte acquires option from Sutro Biopharma to expand rights to make cell-free extractDecember 17, 2022 | finance.yahoo.comInvestors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 54% over the last yearDecember 10, 2022 | finance.yahoo.comSutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022November 20, 2022 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Sutro Biopharma, Inc. (NASDAQ:STRO) RevenuesNovember 11, 2022 | finance.yahoo.comHow Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%November 11, 2022 | finance.yahoo.comSutro Biopharma Third Quarter 2022 Earnings: Misses ExpectationsNovember 8, 2022 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comSutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated MilestonesNovember 3, 2022 | finance.yahoo.comSutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionOctober 24, 2022 | finance.yahoo.comSutro Biopharma Announces Departure of Chief Medical OfficerOctober 21, 2022 | finance.yahoo.comWall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to TradeOctober 5, 2022 | finance.yahoo.comDoes Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect?September 26, 2022 | finance.yahoo.comA Sutro Biopharma, Inc. (NASDAQ:STRO) insider increased their holdings by 4.3% last yearSeptember 24, 2022 | uk.finance.yahoo.comSutro Biopharma, Inc. (STRO)September 1, 2022 | finance.yahoo.comSutro Biopharma to Present at the 2022 Wells Fargo Healthcare ConferenceAugust 29, 2022 | finance.yahoo.comHow Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 288%See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Company Calendar Last Earnings11/08/2022Today2/03/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees224Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.67 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+176.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,540,000.00 Net Margins-175.85% Pretax Margin-172.27% Return on Equity-53.85% Return on Assets-34.30% Debt Debt-to-Equity Ratio0.03 Current Ratio5.95 Quick Ratio5.95 Sales & Book Value Annual Sales$61.88 million Price / Sales6.60 Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book1.30Miscellaneous Outstanding Shares57,470,000Free Float53,222,000Market Cap$408.61 million OptionableNot Optionable Beta0.88 Key ExecutivesWilliam J. NewellPresident, Chief Executive Officer & DirectorEdward C. AlbiniChief Financial Officer & SecretaryTrevor HallamChief Scientific Officer & President-ResearchShabbir T. AnikChief Technical Operations OfficerCraig BermanVice President-Clinical DevelopmentKey CompetitorsTarsus PharmaceuticalsNASDAQ:TARSKodiak SciencesNASDAQ:KODMeiraGTxNASDAQ:MGTXIcosavaxNASDAQ:ICVXSorrento TherapeuticsNASDAQ:SRNEView All CompetitorsInsiders & InstitutionsBailard Inc.Bought 20,300 shares on 2/2/2023Ownership: 0.035%SG Americas Securities LLCSold 2,534 shares on 2/2/2023Ownership: 0.033%ProShare Advisors LLCBought 11,690 shares on 2/2/2023Ownership: 0.020%New York State Common Retirement FundBought 12,271 shares on 1/30/2023Ownership: 0.055%Allspring Global Investments Holdings LLCBought 21,398 shares on 1/23/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions STRO Stock - Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares. View STRO analyst ratings or view top-rated stocks. What is Sutro Biopharma's stock price forecast for 2023? 5 brokerages have issued 1 year target prices for Sutro Biopharma's stock. Their STRO share price forecasts range from $15.00 to $25.00. On average, they expect the company's stock price to reach $19.67 in the next year. This suggests a possible upside of 170.1% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts. How have STRO shares performed in 2023? Sutro Biopharma's stock was trading at $8.08 at the beginning of the year. Since then, STRO shares have decreased by 9.9% and is now trading at $7.28. View the best growth stocks for 2023 here. When is Sutro Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our STRO earnings forecast. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.22. The business earned $25.15 million during the quarter, compared to analysts' expectations of $11.35 million. Sutro Biopharma had a negative net margin of 175.85% and a negative trailing twelve-month return on equity of 53.85%. What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Sutro Biopharma's stock symbol? Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO." Who are Sutro Biopharma's major shareholders? Sutro Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (0.05%), Allspring Global Investments Holdings LLC (0.05%), Bailard Inc. (0.04%), SG Americas Securities LLC (0.03%), ProShare Advisors LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Arturo Md Molina, John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sutro Biopharma's stock price today? One share of STRO stock can currently be purchased for approximately $7.28. How much money does Sutro Biopharma make? Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $418.38 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. How many employees does Sutro Biopharma have? The company employs 224 workers across the globe. How can I contact Sutro Biopharma? Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com. This page (NASDAQ:STRO) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.